## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.97)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: FOX40 News | 20251210T010925 | Neutral | Relevance: 100%
-  Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

**2. Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit – DXCM**
- Source: GlobeNewswire | 20251209T220805 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP is reminding investors of DexCom, Inc. (DXCM) about a class action securities lawsuit. The lawsuit alleges that DexCom made material design changes to its glucose monitoring products (G6 and G7) without FDA authorization, rendering them less reliable and potentially harmful. Investors who suffered losses between January 8, 2024, and September 17, 2025, have until December 26, 2025, to request to be appointed as lead plaintiff.

**3. DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM**
- Source: WBOY.com | 20251208T140805 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. (NASDAQ: DXCM) regarding a securities class action lawsuit. Investors who purchased DXCM shares between January 8, 2024, and September 17, 2025, are encouraged to contact the firm to discuss potential lead plaintiff appointment. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, and that the company downplayed these issues.

**4. Pomerantz LLP Pursues Class Action Litigation Against DexCom, Inc. – DXCM**
- Source: KXAN Austin | 20251207T160803 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers, alleging violations of federal securities laws due to materially false and misleading statements made between July 26, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, rendering them less reliable and posing health risks, which led to significant stock price drops following an FDA warning letter, an analyst downgrade, and a critical report. Investors who purchased DexCom securities during this period have until December 26, 2025, to seek appointment as Lead Plaintiff.

**5. Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky to Join Class Action Before December 26, 2025**
- Source: FOX40 News | 20251207T160836 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of shareholders who experienced losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly concealed. Shareholders affected by these alleged misrepresentations are encouraged to contact Levi & Korsinsky to learn about their rights to potential recovery.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 11.3% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 26.7 |
| Current P/E | 32.1 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 1.1% confirms short-term momentum alignment. AM_20 at 7.2% shows strong absolute momentum above own 20MA. Outperforming sector by 9.4pp, stock-specific strength. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (0.86), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.91% (CS: 85) | Strong |
| RSI_14 | 61.8 | Neutral |
| MACD Histogram | 0.86 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.887x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $66.33
- **Stop Loss:** $61.97 (6.6% risk)
- **Target:** $75.05 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 68
- **Position Value:** $4,510.44
- **Portfolio %:** 4.51%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*